行业走势图 -10% 0% 10% 19% 29% 2025-02 2025-06 2025-10 食品饮料 沪深300 数据来源：聚源 相关研究报告 食品饮料 2026 年 01 月 30 日 投资评级：看好（维持） 2025 年以来，白酒的机构配置比例持续降低，业绩也在承压，股价面临估值和 业绩双杀。但从白酒板块历史上看，白酒一直跟随宏观环境呈现出较强周期性， 现在随着库存出清，行业从被动应对进入主动调整，预计 2026 年预期逐步筑底 企稳，后续随着居民资产负债表修复，消费意愿提升，从而进入下一个上行周期。 白酒股价下行，基金持仓再创新低 四季度以来白酒板块受指数基金卖出权重股影响表现不佳，基金重仓白酒比例由 2025Q3 的 3.2%回落至 2025Q4 的 2.9%水平，环比回落 0.3pct。如果观察全市场 基金口径，基金重仓白酒比例由 2025Q3 的 5.5%回落到 2025Q4 的 5.1%。这反 映出主动权益与被动基金均在减配白酒。主要原因是 2025 年以来，白酒产品价 格持续下行，市场对行业长期需求有所担忧。主动基金前十大重仓股中白酒仅有 贵州茅台，且从 Q3 末第 7 位下降至 Q4 ...

传媒/游戏Ⅱ 吉比特（603444.SH） 投资评级：买入（维持） | 日期 | 2026/1/29 | | --- | --- | | 当前股价(元) | 475.50 | | 一年最高最低(元) | 668.00/198.21 | | 总市值(亿元) | 342.56 | | 流通市值(亿元) | 342.56 | | 总股本(亿股) | 0.72 | | 流通股本(亿股) | 0.72 | | 近 3 个月换手率(%) | 157.33 | 股价走势图 数据来源：聚源 -80% 0% 80% 160% 240% 2025-02 2025-06 2025-10 吉比特 沪深300 相关研究报告 《《九牧之野》上线在即，看好新游持 续驱动公司成长—公司信息更新报 告》-2025.12.12 《出海及新游或持续驱动业绩高增长 —公司信息更新报告》-2025.10.29 《Q2 业绩高增，高分红延续，新游及 出海驱动成长 —公司信息更新报告》 -2025.8.20 方光照（分析师） fangguangzhao@kysec.cn 2026 年 01 月 30 日 证书编号：S0790520030004 2025 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][3] Core Views - The company is expected to see significant growth in 2025, with a forecasted net profit attributable to shareholders of 1.69-1.86 billion yuan, representing a year-on-year increase of 79-97%. The non-recurring net profit is projected to be 1.65-1.80 billion yuan, reflecting an 88-105% increase [3][4] - The anticipated growth is primarily driven by the new game launches in 2025, including "杖剑传说," "问剑长生," and "道友来挖宝," which are expected to contribute incremental profits [3][4] - The company has a strong long-term operational capability, as evidenced by the performance of existing games and the potential of new releases to enhance revenue [4][5] Financial Summary - The company's revenue is projected to increase from 4.185 billion yuan in 2023 to 6.102 billion yuan in 2025, with a year-on-year growth rate of 65.1% [6][8] - The net profit attributable to shareholders is expected to rise from 1.125 billion yuan in 2023 to 1.746 billion yuan in 2025, marking an 84.8% increase [6][8] - The gross margin is forecasted to improve from 88.5% in 2023 to 93.7% in 2025, indicating strong profitability [6][9] - The price-to-earnings (P/E) ratio is projected to decrease from 30.4 in 2023 to 19.6 in 2025, suggesting a more attractive valuation over time [6][8] Game Development and Market Position - The company is focusing on high-frequency content updates and building a trading ecosystem to create enduring games, with "问道手游" showing resilience in revenue generation [4][5] - Upcoming titles like "九牧之野" and "道友来挖宝" are expected to perform well based on initial rankings and user engagement metrics [4][5] - The company has several projects in development, including unique game mechanics that are expected to contribute to future revenue growth [5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company is expected to achieve significant growth in net profit, with a forecasted net profit of 83 million yuan for 2025, representing a year-on-year increase of 153.1%. The net profit for 2026 and 2027 is projected to be 158 million yuan and 297 million yuan, respectively [4][7] - The company has a strong positioning in the AI programming sector, with the launch of two AI programming products, SnapDevelop and EazyDevelop, which are expected to enhance development efficiency and attract a wide user base [5] Financial Summary - The company’s revenue is projected to grow from 418 million yuan in 2025 to 785 million yuan in 2027, with year-on-year growth rates of 29.4%, 35.8%, and 38.1% respectively [7] - The gross profit margin is expected to improve from 48.8% in 2025 to 58.0% in 2027, indicating enhanced profitability [10] - The earnings per share (EPS) is forecasted to increase from 0.69 yuan in 2025 to 2.45 yuan in 2027, reflecting strong earnings growth [7][10]

Group 1: Macro Economic Insights - The Federal Reserve maintained interest rates in the range of 3.5%-3.75% during the January FOMC meeting, indicating a stable economic expansion in the U.S. [5][6] - The labor market's downward trend and inflation risks have eased, suggesting that maintaining stable interest rates is the best choice for the short term [7][8] - Market reactions post-FOMC meeting showed little change in risk appetite, with the Dow Jones and Nasdaq indices experiencing slight increases [8] Group 2: Industrial Profit Insights - In December 2025, industrial profits for large-scale enterprises grew by 0.6% year-on-year, marking a return to positive growth after three consecutive years of decline [10][11] - The profit structure within the industrial sector is showing signs of divergence, with the equipment manufacturing sector becoming a significant driver of profit growth [13] - High-tech manufacturing profits increased by 13.3% year-on-year, significantly outpacing the average growth of all industrial sectors [13] Group 3: Pre-prepared Food Industry - The Chinese government is drafting national standards for pre-prepared foods to enhance consumer protection and industry quality [25][26] - The introduction of these standards is expected to raise compliance costs for smaller companies, leading to a market reshuffle favoring larger, established firms [27][28] - As industry standards improve, leading companies are likely to benefit from enhanced brand trust and market share [29] Group 4: Chemical Industry Developments - The Ministry of Ecology and Environment is pushing for the exit of outdated capacity in the chlor-alkali industry, particularly in PVC production, due to environmental concerns [31][32] - The implementation of the Minamata Convention will increase production costs for companies using mercury-based processes, accelerating the exit of less competitive firms [33] - Beneficiaries of these changes include companies like Xinjiang Tianye and Zhongtai Chemical, which are better positioned to adapt to the new regulatory environment [34] Group 5: Medical Industry Insights - Kailaiying, a leading small molecule CDMO, is transitioning towards a dual business model that includes emerging sectors like peptides and small nucleic acids, showing strong growth potential [35][36] - The company is expanding its peptide production capacity significantly to meet the rising demand for GLP-1 drugs, positioning itself favorably in a high-growth market [36] - The overall investment environment in the healthcare sector is improving, which may lead to increased demand for CDMO services [37]

Investment Rating - The investment rating for the company is "Buy" (首次) [1] Core Insights - The company is a leading small molecule CDMO with over 25 years of experience, currently transitioning from a single small molecule business to a dual-driven model of "small molecule + emerging business" [5][17] - The new business segment is experiencing rapid growth, contributing significantly to revenue, while traditional business remains resilient [5][6] - The company is expected to achieve net profits of 1.16 billion, 1.30 billion, and 1.51 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 3.23, 3.59, and 4.18 yuan [5] Financial Summary and Valuation Metrics - Revenue projections for 2025, 2026, and 2027 are 6.66 billion, 7.69 billion, and 8.94 billion yuan respectively, with year-over-year growth rates of 14.7%, 15.4%, and 16.3% [8] - The company’s gross margin is projected to be around 42% for 2025, with a net margin of 17.5% [8] - The current P/E ratios are 31.0, 27.8, and 23.9 for 2025, 2026, and 2027 respectively [8] Business Development and Strategy - The company is focusing on expanding its capabilities in the peptide and small nucleic acid sectors, with significant investments in production capacity [6][79] - As of H1 2025, the new business segment generated 756 million yuan in revenue, a 51.22% increase year-over-year, accounting for 23.71% of total revenue [6] - The company has established partnerships with major pharmaceutical companies, enhancing its market presence and customer base [44] Industry Trends - The global healthcare investment environment is gradually recovering, with a total investment of 63.88 billion USD in 2025, marking a 10.13% increase year-over-year [47] - The domestic healthcare investment market is also improving, with a total of 73.78 billion yuan in 2025, a 39.05% increase year-over-year [53] - The global CDMO market is expected to grow significantly, with the small molecule CDMO/CMO market projected to reach 112 billion USD by 2029, growing at a CAGR of 16.6% [65]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected performance that will exceed the market by more than 20% [3][8]. Core Insights - The company forecasts a significant increase in net profit attributable to shareholders for 2025, projecting a growth of 50.41% to 65.86%, with expected net profit ranging from 76.90 million to 84.80 million yuan compared to 51.13 million yuan in 2024 [3]. - The company has successfully developed low-temperature superconducting RF cables for quantum computing applications, marking it as one of the early adopters in this field within China [5]. - The company has established itself in the defense sector, with orders gradually recovering, and is also benefiting from the accelerated deployment of domestic satellite internet constellations [3][5]. Financial Summary - The company’s revenue is projected to grow from 763 million yuan in 2024 to 849 million yuan in 2025, reflecting a year-over-year increase of 11.4% [6]. - The net profit is expected to rise from 51 million yuan in 2024 to 83 million yuan in 2025, representing a year-over-year growth of 61.7% [6]. - The earnings per share (EPS) is forecasted to increase from 0.27 yuan in 2024 to 0.44 yuan in 2025, with a corresponding price-to-earnings (P/E) ratio of 101.1x for 2025 [6][9].

2026 年 01 月 29 日 宏观研究团队 美联储独立性和新主席换届是市场更关注的点 ——1 月 FOMC 会议点评 何宁（分析师） 潘纬桢（分析师） hening@kysec.cn 证书编号：S0790522110002 声明及发布会要点 1. 美联储在此次会议上宣布维持利率水平在 3.5%-3.75%区间。资产负债表政策 方面，按照 2025 年 12 月的计划继续执行。 2. 暂停降息，再次出现 2 张反对票。在声明中，美联储的措辞同 2025 年 12 月 份相比有一定的变化。美联储认为当前美国经济活动稳步扩张，2025 年 12 月则 认为经济活动正以温和的速度扩张。就业方面，美联储认为就业增长依然缓慢， 失业率已出现企稳迹象。2025 年 12 月则认为失业率有上升趋势；通胀方面，认 为通胀仍处于略高水平，与 2025 年 12 月表述基本相同。此外，美联储删除了 2025 年 12 月份关于风险平衡的变化表述，说明其认为当前货币政策短期无需调 整。此外，本次会议中再次出现 2 张反对票。米兰与沃勒认为应该继续降息 25bp， 随着新主席换届的时间越来越近，美联储内部的分歧或继续显性化。 相关 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation of performance exceeding the market by more than 20% [3][8]. Core Insights - The company forecasts a significant increase in net profit attributable to shareholders for 2025, projecting a growth of 50.41% to 65.86%, with expected net profit ranging from 76.90 million to 84.80 million yuan compared to 51.13 million yuan in 2024 [3][6]. - The company has successfully developed low-temperature superconducting RF cables for quantum computing applications, marking it as one of the early adopters in the domestic market [5][6]. - The company has established itself in the defense sector, with orders gradually recovering, and is also benefiting from the accelerated deployment of domestic satellite internet constellations [3][4]. Financial Summary - Revenue is projected to increase from 763 million yuan in 2024 to 849 million yuan in 2025, reflecting a year-over-year growth of 11.4% [6][9]. - The net profit is expected to rise from 51 million yuan in 2024 to 83 million yuan in 2025, representing a year-over-year increase of 61.7% [6][9]. - The company's gross margin is forecasted to be 33.3% in 2025, with a net margin of 9.7% [6][10]. - Earnings per share (EPS) is projected to increase from 0.27 yuan in 2024 to 0.44 yuan in 2025 [6][9].

旅游及景区 旅游及景区 2026 年 01 月 28 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -10% 0% 10% 19% 29% 38% 2025-01 2025-05 2025-09 旅游及景区 沪深300 相关研究报告 海南专题报告：风宜长物放眼量，自贸港赶海正当时 风险提示：宏观经济波动风险、政策落地不及预期、高端消费复苏不及预期。 ——行业深度报告 | 初敏（分析师） | 叶彬慧（联系人） | | --- | --- | | chumin@kysec.cn | yebinhui@kysec.cn | | 证书编号：S0790522080008 | 证书编号：S0790124070053 | yebinhui@kysec.cn 证书编号：S0790124070053 海南自贸港：双向循环战略支点，枢纽功能徐徐演进 开 源 证 券 证 券 研 海南自贸港是中央基于全球化格局深度调整、全球供应链加速重构背景，高标准 建设的中国特色自由贸易港，享有国内高规格、系统性的开放试验授权。对比全 球成熟的自贸港枢纽，依托内地超大规模统一市场的腹地优势和最大经济特区禀 赋，海南聚焦打造三大核心定位： ...